[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-383069-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-383069-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","cancer-screening-in-people-living-with-hiv-review","Cancer screening in people living with HIV - Review","","Background: Cancer is the leading cause of mortality in people living with HIV (PWH) and is projected to contribute to an increasing share of deaths as PWH age. Methods: This literature review compiles recent advances in cancer screening and screening performance in PWH, including benefits, harms, and cost-effectiveness, and discusses unmet needs and tailored screening strategies. Findings: Incidence and mortality from screenable cancers are higher in PWH, with diagnoses often at younger ages and/or later stages. Interpretation: Late diagnosis has devastating consequences, so enhancing early detection is essential, with urgent research into risk-personalized approaches to improve outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/cancer-screening-in-people-living-with-hiv-review/383069/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/cancer-screening-in-people-living-with-hiv-review/383069.png","ImageObject",300,407,{"name":42,"@type":43},"Mary Man","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"Why is cancer screening especially important for people living with HIV (PWH)?","Question",{"text":63,"@type":64},"Cancer is a leading cause of death in PWH, and diagnoses are often made at younger ages and/or more advanced stages. Because late diagnosis has serious consequences, improving early detection through screening is essential.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What does the review say about cancer incidence and outcomes in PWH compared with the general population?",{"text":68,"@type":64},"Incidence and mortality from screenable cancers are higher in PWH. Cancers can occur at younger ages, be diagnosed at later stages, and are associated with higher mortality.",{"name":70,"@type":61,"acceptedAnswer":71},"What screening evidence exists for lung cancer in PWH?",{"text":72,"@type":64},"Low-dose computed tomography (LDCT) reduces lung cancer mortality in general-population randomized trials, but in PWH the evidence is limited to a few small observational studies with heterogeneous criteria and short follow-up.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},383069,1790793286,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145},7421720224475,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","DOI: 10. 1002/cam4 .6585  \nREVIEW  \nCancer screening in people living with HIV  \nMar Masiá1,2  | Ana Gutiérrez-Ortiz de la Tabla3 | Félix Gutiérrez2,4  \n1Infectious Diseases Division, Hospital General Universitario de Elche, Elche, Spain  \n2Centro de Investigación en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain  \n3Medical Oncology Department, Gregorio Marañón University Hospital, Madrid, Spain  \n4Department of Clinical Medicine, Miguel Hernández University, San Juande Alicante, Spain  \nCorrespondence  \nMar Masiá, Infectious Diseases Division, Hospital General Universitario de Elche, Elche, Spain. [Email:](Email: mmasia@umh.es)[ mmasia@umh.es](Email: mmasia@umh.es)  \nFélix Gutiérrez, Clinical Medicine Department, Miguel Hernández University, San Juan de Alicante, Spain. [Email:](Email: gutierrez_fel@gva.es)[ gutierrez_fel@gva.es](Email: gutierrez_fel@gva.es)  \nFunding information  \nConselleria de Innovación, Universidades, Ciencia y Sociedad Digital, Generalitat Valenciana, Grant/ Award Number: AICO/2021/205; European Regional Development Fund, Grant/Award Number: CB21/13/00011 and RD16/0025/0038; Instituto de Salud Carlos III, Grant/Award Number: COV20/00005, PI18/01861, CM19/00160, CM20/00066, PI16/01740 and PI22/01949  \n1 | INTRODUCTION  \nAbstract  \nBackground: Cancer is the leading cause of mortality in people living with HIV (PWH) and is expected to account for a growing fraction of deaths as PWH age. Methods: In this literature review, we have compiled the most recent developments in cancer screening and screening performance in PWH, which are currently primarily implemented in well-resourced settings. This includes an assessment of the associated benefits, harms, and cost-effectiveness. The article also addresses unmet needs and potential strategies for tailored screening in the HIV population.  \nFindings: Incidence and mortality due to screenable cancer are higher in PWH than in the general population, and diagnosis is frequently made at younger ages and/or at more advanced stages, the latter amenable to improved screening. Adequate evidence on the benefits of screening is lacking for most cancers in the HIV population, in whom standard practice may be suboptimal. While cancer surveillance has helped reduce mortality in the general population, and interest in risk-based strategies is growing, implementation of screening programs in the HIV care settings remains low.  \nInterpretation: Given the devastating consequences of a late diagnosis, enhancing early detection of cancer is essential for improving patient outcomes. Thereis an urgent need to extend the investigation in cancer screening performance to PWH, evaluating whether personalized measures according to individual risk could result in higher efficiency and improve patient outcomes.  \nKEYWORDS  \nnon-AIDS cancer, screening, screening performance, surveillance  \ntherapy (ART) but still lags somewhat behind that of the general population.1 One reason is probably the large,  \nLife expectancy in people living with HIV (PWH) has risen persistent difference in the comorbidity burden between dramatically since the advent of combination antiretroviral populations, with cancer playing a central role in PWH.2  \nThis is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.  \n© 2023 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.  \nMASIÁ et al.  \n|  \n20591  \nThe so-called non-AIDS-defining cancers (NADC), currently the dominant malignancies,3 are now the leading cause of death among PWH.4 The incidence and prevalence of numerous malignancies are much higher in PWH than in the general population. Moreover, they can occur at younger ages, be diagnosed at later stages, and cause higher mortality.5–8  \nAlthough cancer is a major factor contributing to decreased survival in PWH, and","cbCaijL0Zgaif5TO","https://ap.wps.com/l/cbCaijL0Zgaif5TO","pdf",472465,14,"English","# Abstract\n# Key findings and interpretation\n# Introduction\n# Screening for lung cancer\n## Screening tests\n## Screening recommendations and performance in PWH","[{\"question\":\"Why is cancer screening especially important for people living with HIV (PWH)?\",\"answer\":\"Cancer is a leading cause of death in PWH, and diagnoses are often made at younger ages and/or more advanced stages. Because late diagnosis has serious consequences, improving early detection through screening is essential.\"},{\"question\":\"What does the review say about cancer incidence and outcomes in PWH compared with the general population?\",\"answer\":\"Incidence and mortality from screenable cancers are higher in PWH. Cancers can occur at younger ages, be diagnosed at later stages, and are associated with higher mortality.\"},{\"question\":\"What screening evidence exists for lung cancer in PWH?\",\"answer\":\"Low-dose computed tomography (LDCT) reduces lung cancer mortality in general-population randomized trials, but in PWH the evidence is limited to a few small observational studies with heterogeneous criteria and short follow-up.\"}]","Cancer screening in people living with HIV - Review | PDF",1790253980,35]